On November 4, 2021 Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, reported that three abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted as poster presentations at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to be held from December 11-14, 2021 (Press release, Geron, NOV 4, 2021, View Source [SID1234594377]). The abstracts are available on the ASH (Free ASH Whitepaper) website at www.hematology.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The abstracts for this year’s ASH (Free ASH Whitepaper) Meeting reflect the breadth of ongoing activity with imetelstat from pre-clinical studies in a new indication, as well as use of imetelstat as a single agent and in combination with other therapies, to analyses of clinical data supporting our Phase 3 development," said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer. "We look forward to continued work in these areas as we expand the potential applications for imetelstat in hematologic malignancies."
Clinical Data – Lower Risk Myelodysplastic Syndromes (MDS)
Abstract Title: On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)
The abstract describes new analyses of data from the IMerge Phase 2 clinical trial. In the analyses, a significant correlation was observed between achieving an optimal pharmacodynamic (PD) effect in imetelstat-treated patients with durable red blood cell transfusion independence (RBC-TI). In addition, a trend of improved overall survival rate was seen in patients who achieved optimal PD effect. The authors believe these results demonstrate a potential link between imetelstat activity and clinical efficacy. Additionally, patients in IMerge Phase 2 who achieved an optimal PD effect with imetelstat treatment did not have higher rates of cytopenias or liver enzyme elevations compared to patients without an optimal PD effect.
Poster Presentation Details
Abstract: #2598
Date: Sunday, December 12, 2021
Time: 6:00 p.m. – 8:00 p.m. ET
Pre-Clinical Data – Pediatric Acute Myeloid Leukemia
Abstract Title: Imetelstat Significantly Reduces Leukemia Stem Cells in Patient-Derived Xenograft Models of Pediatric AML
The abstract reports results from pre-clinical studies of imetelstat in pediatric acute myeloid leukemia (AML) cell lines (in vitro studies) and patient derived (PDX) mouse models (in vivo studies). The efficacy of imetelstat either as a single agent or in combination with chemotherapy or azacitidine was evaluated. In cell line experiments, imetelstat treatment resulted in cell apoptosis/death of leukemia stem cells (LSCs) in a dose-dependent manner. In the in vivo studies, imetelstat treatment reduced LSC numbers and increased median survival in mice. In addition, combining imetelstat with chemotherapy or azacitidine further enhanced activity against LSCs. The authors conclude that the results of these pre-clinical studies suggest imetelstat could represent an effective therapeutic strategy for pediatric AML.
Poster Presentation Details
Abstract: #3352
Date: Monday, December 13, 2021
Time: 6:00 p.m. – 8:00 p.m. ET
Trials in Progress Poster Presentation – IMpactMF Phase 3 trial in Refractory MF
Abstracts for this category describe innovative clinical trials that have not reached their primary endpoint to provide opportunities for early engagement and collaboration amongst investigators, translational research, clinical and industry investigators, statisticians and regulators.
Abstract Title:A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
Poster Presentation Details
Abstract: #1503
Date: Saturday, December 11, 2021
Time: 6:00 p.m. – 8:00 p.m. ET
In accordance with ASH (Free ASH Whitepaper) policies, abstracts submitted to the ASH (Free ASH Whitepaper) Annual Meeting are embargoed from the time of submission. To be eligible for presentation at the ASH (Free ASH Whitepaper) Annual Meeting, any additional data or information to be presented at the Annual Meeting may not be made public before the presentation. The posters will be available at www.geron.com/r-d/publications following the ASH (Free ASH Whitepaper) Annual Meeting presentations.
About Imetelstat
Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in myeloid hematologic malignancies. Data from Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis and potential disease-modifying activity. Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower risk MDS who are refractory or resistant to an erythropoiesis-stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus associated kinase (JAK) inhibitor treatment.